News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Discusses Phase II Cardiovascular Clinical Study
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 31, 2006--Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI's partner Cook Group Inc. presented promising preliminary observations at the 18th Annual Transcatheter
View HTML
Toggle Summary AVI BioPharma Publishes Preclinical Data Showing NEUGENE Antisense Inhibition of Multiple Strains of Influenza A Virus
Business Editors/Biotech Writers PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced publication of preclinical results from studies carried out by an international team of researchers showing the ability of NEUGENE(R) antisense to inhibit multiple
View HTML
Toggle Summary AVI BioPharma Presents Successful Trial Results Using NEUGENE Antisense to Alter Drug Metabolism in Humans
Business Editors/Biotech Writers PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 19, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented data and analysis from four NEUGENE(R) antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in
View HTML
Toggle Summary AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 18, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced the initiation of a clinical program to assess the safety and effectiveness of AVI-5126, a new generation of NEUGENE(R) antisense drug for treating coronary vascular disease.
View HTML
Toggle Summary AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 4, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety,
View HTML
Toggle Summary AVI BioPharma Presents Positive Preclinical Data Evaluating NEUGENE Antisense Compounds Against Influenza A Virus and the E. coli Bacteria
Business Editors/Biotech Writers BIOWIRE2K ICAAC 2006 PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 29, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE(R) antisense technology against influenza A and E. coli infection.
View HTML
Toggle Summary AVI BioPharma to Present at UBS Global Life Sciences Conference
PORTLAND, Ore.--(BUSINESS WIRE)--Sept. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that on Wednesday, Sept. 27, 2006, Alan P. Timmins, AVI's president and COO, will present the company's overall strategy and progress to date at the UBS Global Life Sciences Conference to be held at
View HTML
Toggle Summary AVI BioPharma Incorporated 2006 Second Quarter Financial Results Conference Call Transcript
Moderator: Denis Burger August 8, 2006 8:00 a.m. Pacific Time Operator: Welcome to the AVI BioPharma 2006 Second Quarter Financial Results conference call. At this time, all participants are in a listen–only mode. Following management’s prepared remarks, we’ll hold a Q&A session.
View HTML
Toggle Summary AVI BioPharma Announces Publication of Positive Results from New Class of Antibiotics Using NEUGENE Antisense Technology
PORTLAND, Ore., Aug 09, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq:AVII) today announced the publication of positive preclinical results from a new class of antisense-based antibiotics, called NeuBiotics. The article, titled "Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino
View HTML
Toggle Summary AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time
PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and six months ended June 30, 2006. The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.